Basic Information
| RNALocate ID: | RLID:11003368 |
| RNA Symbol: | hsa-miR-411-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-411 |
| RNA ID: | miRBase:MIMAT0003329 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23666971 |
| Tissue/Cell Line: | Follicular fluid |
| Method: | Microarray |
| Description: | The TaqMan miRNA Array Card version 3.0, which includes 766 mature miRNAs, detected the presence of miRNAs in both the microvesicles and the supernatant. A total of 120 miRNAs (cycle threshold [Ct] <37) were found in the in microvesicles extracted from 8 mL fresh follicular fluid, and 82 miRNAs (Ct <37) were expressed in 500 uL supernatant (Table 2). Data are collected from Table 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002470 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:11003365 | Exosome | Serum | 18589210 |
| RLID:11003366 | Exosome | Plasma | 23663360 |
| RLID:11003367 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
| RLID-D:11000167 | Exosome | Blood|B lymphoblastoid cells|Endothelial cells|Mast cells | |
| RLID-D:11000542 | Microvesicle | Blood|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-411-5p | Peripheral arterial disease | MNDR-E-MI-48116 |
| MNDR | hsa-miR-411-5p | Oral squamous cell carcinoma | MNDR-E-MI-48117 |
| MNDR | hsa-miR-411-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-48118 |
| MNDR | hsa-miR-411-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-48119 |
| MNDR | hsa-miR-411-5p | Lymphoma | MNDR-E-MI-48120 |
| MNDR | hsa-miR-411-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-48121 |
| MNDR | hsa-miR-411-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-48122 |
| MNDR | hsa-miR-411-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-48123 |
| MNDR | hsa-miR-411-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-48124 |
| MNDR | hsa-miR-411-5p | Her2-receptor positive breast cancer | MNDR-E-MI-48125 |
| MNDR | hsa-miR-411-5p | Niemann-pick disease type c | MNDR-E-MI-48126 |
| MNDR | hsa-miR-411-5p | Prostate cancer | MNDR-E-MI-48127 |
| MNDR | hsa-miR-411-5p | Alzheimer disease | MNDR-E-MI-48128 |
| MNDR | hsa-miR-411-5p | Dysautonomia familial | MNDR-E-MI-48129 |
| MNDR | hsa-miR-411-5p | Head and neck cancer | MNDR-E-MI-48130 |
| MNDR | hsa-miR-411-5p | Lung cancer | MNDR-E-MI-48131 |
| MNDR | hsa-miR-411-5p | Endometrial cancer | MNDR-E-MI-48132 |
| MNDR | hsa-miR-411-5p | Down syndrome | MNDR-E-MI-48133 |
| MNDR | hsa-miR-411-5p | Parkinson disease | MNDR-E-MI-48134 |
| MNDR | hsa-miR-411-5p | Niemann-pick disease | MNDR-E-MI-48135 |
| MNDR | hsa-miR-411-5p | Breast cancer | MNDR-E-MI-48136 |
| MNDR | hsa-miR-411-5p | Thyroid cancer | MNDR-E-MI-48137 |
| MNDR | hsa-miR-411-5p | Pancreatic cancer | MNDR-E-MI-48138 |
| MNDR | hsa-miR-411-5p | Melanoma | MNDR-E-MI-48139 |
| MNDR | hsa-miR-411-5p | Nephroblastoma | MNDR-E-MI-48140 |
| MNDR | hsa-miR-411-5p | Colon cancer | MNDR-E-MI-48141 |
| MNDR | hsa-miR-411-5p | Ischemic attack transient | MNDR-E-MI-48142 |
| MNDR | hsa-miR-411-5p | Colon adenocarcinoma | MNDR-E-MI-48143 |
| MNDR | hsa-miR-411-5p | Ovarian cancer | MNDR-E-MI-48144 |
| MNDR | hsa-miR-411-5p | Prostate adenocarcinoma | MNDR-E-MI-48145 |
| MNDR | hsa-miR-411-5p | Carcinoma ductal breast | MNDR-E-MI-48146 |
| MNDR | hsa-miR-411-5p | Glioblastoma | MNDR-E-MI-48147 |
| MNDR | hsa-miR-411-5p | Astrocytoma | MNDR-E-MI-48148 |
| MNDR | hsa-miR-411-5p | Glioma | MNDR-E-MI-48149 |
| MNDR | hsa-miR-411-5p | Temporal lobe epilepsy | MNDR-E-MI-48150 |
| MNDR | hsa-miR-411-5p | Osteosarcoma | MNDR-E-MI-48151 |
| MNDR | hsa-miR-411-5p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-48152 |
| MNDR | hsa-miR-411-5p | Uterine cancer | MNDR-E-MI-48153 |
| MNDR | hsa-miR-411-5p | Gastric adenocarcinoma | MNDR-E-MI-48154 |
| MNDR | hsa-miR-411-5p | Cervical squamous cell carcinoma | MNDR-E-MI-48155 |
| MNDR | hsa-miR-411-5p | Bone-invasive pituitary adenoma | MNDR-E-MI-48156 |
| MNDR | hsa-miR-411-5p | Lung adenocarcinoma | MNDR-E-MI-48157 |
| MNDR | hsa-miR-411-5p | Adrenocortical carcinoma | MNDR-E-MI-48158 |
| MNDR | hsa-miR-411-5p | Thyroid carcinoma | MNDR-E-MI-48159 |
| MNDR | hsa-miR-411-5p | Ovarian carcinoma | MNDR-E-MI-48160 |
| MNDR | hsa-miR-411-5p | Bladder urothelial carcinoma | MNDR-E-MI-48161 |
| MNDR | hsa-miR-411-5p | Pancreatic adenocarcinoma | MNDR-E-MI-48162 |
| MNDR | hsa-miR-411-5p | Carcinoma renal cell | MNDR-E-MI-48163 |
| MNDR | hsa-miR-411-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-48164 |
| MNDR | hsa-miR-411-5p | Renal clear cell carcinoma | MNDR-E-MI-48165 |
| MNDR | hsa-miR-411-5p | Synovial sarcoma | MNDR-E-MI-48166 |
| MNDR | hsa-miR-411-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-48167 |
| MNDR | hsa-miR-411-5p | Breast invasive carcinoma | MNDR-E-MI-48168 |
| MNDR | hsa-miR-411-5p | Hepatocellular carcinoma | MNDR-E-MI-48169 |
| MNDR | hsa-miR-411-5p | Rheumatoid arthritis | MNDR-E-MI-48170 |
| MNDR | hsa-miR-411-5p | Abdominal aortic aneurysm | MNDR-E-MI-48171 |
| MNDR | hsa-miR-411-5p | Osteoarthritis | MNDR-E-MI-48172 |
| MNDR | hsa-miR-411-5p | Crohn disease | MNDR-E-MI-48173 |
| MNDR | hsa-miR-411-5p | Colorectal cancer | MNDR-E-MI-48174 |
| MNDR | hsa-miR-411-5p | Esophageal squamous cell cancer | MNDR-E-MI-48175 |
| MNDR | hsa-miR-411-5p | Ependymoma | MNDR-E-MI-48176 |
| MNDR | hsa-miR-411-5p | Stroke lacunar | MNDR-E-MI-48177 |
| MNDR | hsa-miR-411-5p | Breast cancer her3+ negative | MNDR-E-MI-48178 |
| MNDR | hsa-miR-411-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-48179 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | FOXO1 | Homo sapiens | RR00576689 |
TOP